Investigating how Egfl6 affects immune responses in uterine cancer
Official title: The Role of Egfl6 in Tumor Immunity
Funded at Magee-Women's Res Inst and Foundation · NIH-11128875 · Data updated 2026-11-12
This study is looking at a protein called Egfl6 to see how it affects the immune system's response to a type of endometrial cancer called uterine serous carcinoma, with the hope that understanding this could help develop better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Magee-Women's Res Inst and Foundation NIH-funded |
| Lab location | 1 site (Pittsburgh, UNITED STATES) |
| Project start | April 1, 2025 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $215,041 |
| NIH project number | 3R01CA276279-02S1 |
| Project ID | NIH-11128875 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with uterine serous carcinoma or those at risk for this type of cancer.
✕Less likely to help
Patients with other types of cancers or those not diagnosed with uterine serous carcinoma may not benefit from this research.
What this research studies
This research focuses on understanding the role of a specific protein, Egfl6, in the immune response to uterine serous carcinomas (USC), a type of endometrial cancer. By analyzing the tumor microenvironment, the study aims to identify how Egfl6 influences the recruitment and function of immune cells that can either suppress or promote tumor growth. The approach involves using animal models to observe the effects of Egfl6 on tumor development and immune cell behavior, which could lead to new immunotherapy strategies for treating USC. Patients may benefit from insights gained that could improve treatment options for this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with uterine serous carcinomas.
How similar studies have gone: Similar research has shown promise in understanding immune responses in other cancer types, but the specific role of Egfl6 in USC is still being explored.
Where this research is happening
-
Magee-Women's Res Inst and Foundation
Pittsburgh, United States Active
Researchers
- Principal investigator: Cascio, Sandra — Magee-Women's Res Inst and Foundation
- Study coordinator: Cascio, Sandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.